Summary
GE HealthCare Technologies Inc. (GEHC) reported relatively flat total revenues of $4.84 billion for the three months ended June 30, 2024, a slight increase of 1% organically, compared to the prior year period. For the six-month period, total revenues remained flat at $9.49 billion. While product sales saw a slight decline, service revenues experienced growth, driven by pricing increases. Profitability showed a positive trend, with operating income increasing by 7% to $608 million for the quarter and by 2% to $1.15 billion for the six months. Net income attributable to GE HealthCare also saw an increase, reaching $428 million for the quarter and $802 million for the six months. The company reported strong performance in its Pharmaceutical Diagnostics (PDx) segment, which grew 12% in the quarter and 10% year-to-date, driven by volume, price, and new product introductions. Conversely, the China market continues to be a headwind, with revenues down 18% for the quarter, impacted by an ongoing anti-corruption campaign and delayed stimulus programs. Geographically, the United States and Canada (USCAN) region showed robust growth of 5% in the quarter, while EMEA was flat and the Rest of World grew 8%. The company has also made progress in its strategic acquisitions, including the acquisition of MIM Software Inc. in April 2024, which is expected to contribute to the Imaging segment. Cash flow from operations was $300 million for the six months, lower than the previous year, leading to a decrease in free cash flow, which management attributes to factors such as higher inventory levels and increased compensation and benefit payments.
Financial Highlights
48 data points| Revenue | $4.84B |
| Gross Profit | $2.00B |
| R&D Expenses | $327.00M |
| SG&A Expenses | $1.07B |
| Operating Expenses | $1.40B |
| Operating Income | $608.00M |
| Net Income | $428.00M |
| EPS (Basic) | $0.94 |
| EPS (Diluted) | $0.93 |
| Shares Outstanding (Basic) | 457.00M |
| Shares Outstanding (Diluted) | 459.00M |
Key Highlights
- 1Total revenues remained largely flat year-over-year for both the three-month ($4.84B) and six-month ($9.49B) periods ended June 30, 2024, with 1% organic growth in the quarter.
- 2Operating income increased by 7% to $608 million for the three months and by 2% to $1.15 billion for the six months, indicating improved operational efficiency and profitability.
- 3Net income attributable to GE HealthCare rose to $428 million for the quarter and $802 million for the six months, demonstrating a healthier bottom line.
- 4The Pharmaceutical Diagnostics (PDx) segment was a strong performer, with revenue growth of 12% in the quarter and 10% year-to-date, driven by volume, pricing, and new product introductions.
- 5The China market continues to face headwinds, with revenues declining 18% in the quarter due to an ongoing anti-corruption campaign and delayed stimulus programs.
- 6Free cash flow for the first six months of 2024 was $92 million, a significant decrease from $189 million in the prior year, impacted by changes in working capital and higher inventory levels.
- 7GE HealthCare completed the acquisition of MIM Software Inc. in April 2024 for approximately $259 million, adding goodwill and intangible assets to the Imaging segment.